晚期肝细胞癌的当前治疗与免疫肿瘤治疗前景
综述阐述中国晚期肝细胞癌治疗现状,指出中国患者以乙型肝炎病毒感染为主、诊断时常为晚期和终末期、预后不佳,亟需合适治疗方案;免疫肿瘤治疗在临床试验中取得 promising 结果并已获批用于多种晚期恶性肿瘤,为晚期肝细胞癌带来新希望。
要点
- 中国晚期肝细胞癌患者以乙型肝炎病毒感染为主,诊断时常为晚期和终末期,预后不佳。
- 晚期肝细胞癌尚无公认的治疗策略,亟需寻找合适的治疗方案。
- 免疫肿瘤治疗基于临床试验结果已获批用于多种晚期恶性肿瘤,为晚期肝细胞癌带来新希望。
核心结论
- 晚期肝细胞癌尚无公认治疗策略,中国患者具有乙型肝炎病毒感染为主、诊断时常为晚期和终末期、预后不佳的特殊性,亟需合适治疗方案。
- 免疫肿瘤治疗基于临床试验的 promising 结果已获批用于多种晚期恶性肿瘤,为晚期肝细胞癌治疗带来新希望。
研究设计与样本
- 综述,总结中国晚期肝细胞癌治疗现状并讨论免疫肿瘤治疗的研究进展。
主要发现
- 中国晚期肝细胞癌患者以乙型肝炎病毒感染为主,诊断时常为晚期和终末期,临床预后不佳。
- 免疫肿瘤治疗近年受到越来越多关注,相关临床试验成功,已有多种免疫肿瘤治疗药物获批用于各种晚期恶性肿瘤。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment of patients with advanced hepatocellular carcinoma (HCC) remains a huge challenge since a widely accepted therapeutic strategy has not been identified. There are some special features in patients with HCC in China, such as are mainly related to hepatitis B virus infection, often diagnosed as advanced or end-stage disease, and usually have a poorer prognosis compared with patients in western countries. Hence, appropriate treatments are urgently needed for these patients. Notably, immune-oncology therapy has been received increased attention in recent years. Based on promising results observed in clinical trials, immune-oncology therapy has been approved for treatment of various malignant diseases and brings a new hope to the treatment of advanced HCC. The review summarizes the current situation of advanced HCC treatment in China and discusses the prospects of immuno-oncology therapy. 晚期肝细胞癌(HCC)的治疗存在巨大挑战,尚无公认的治疗策略。中国HCC患者的起因以乙型肝炎病毒感染为主,诊断时常为晚期和终末期,临床预后不佳,有一定的特殊性,亟需寻找合适的治疗方案。近年来,免疫肿瘤(IO)治疗受到越来越多的关注。随着相关临床试验的成功,已有多种IO治疗药物获批用于各种晚期恶性肿瘤的治疗,也给晚期HCC患者的治疗带来新的希望。文章在阐述中国晚期HCC治疗现状的基础上,对IO治疗在晚期HCC中的研究进展进行了综述。.
引用
- Xu JM. [Current treatment in advanced hepatocellular carcinoma and prospects for immuno-oncology therapy]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28835076. doi:10.3760/cma.j.issn.0253-3766.2017.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。